

ANNUAL REPORT
2018



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER



HONORING THE PAST



EMBRACING THE PRESENT



YOU ARE THE FUTURE!

OVERVIEW

The International Association for the Study of Lung Cancer (IASLC) is the only global organization solely dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists in over 100 countries. Encompassing a wide variety of disciplines, our members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public.

Our mission is to:

- › **EMBRACE THE STUDY** of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies
- › **PROVIDE EDUCATION AND INFORMATION** about lung cancer and other thoracic malignancies to IASLC members, the medical community at large and the public
- › **USE ALL AVAILABLE MEANS** to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world

IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER





INTRODUCTION

The lung cancer field continues to rapidly evolve. In the last year alone, we've seen major therapeutic advances for small cell lung cancer (the first in 30 years) and stage III non-small cell lung cancer (NSCLC); the release of the results of the groundbreaking NELSON trial, showing a 61% reduction in lung cancer deaths in women and a 26% reduction in men through CT screening for high-risk individuals; and the rise of innovative technologies such as liquid biopsy.

As the world's leading organization devoted to lung cancer and other thoracic malignancies, the IASLC continues to play a central role in educating practitioners, patients and the general public on these practice-changing trends. Through our conferences and meetings, scientific projects and research fellowships, over the past year, the IASLC has better equipped the global lung cancer community – from Guangzhou to Toronto – to drive research forward, understand the latest data and ultimately improve outcomes for patients worldwide.

But it is only with our members that this has been possible. The IASLC and its mission benefit enormously from our corporate partnerships, non-profit collaborations and, especially, the hard work and commitment of our members, leadership and staff. For evidence of this, look no further than former CEO and longtime member Dr. Fred Hirsch, who departed the IASLC in October 2018 after shepherding the association through five years of tremendous growth, change and development.

To put it simply, the IASLC draws its strength from the contributions, dedication and passion of many people. It is with this in mind we approach a critical new stage in the life of our association. In 2019, we will be recommitting ourselves to providing our members with a world class experience, making the necessary investments in technology and talent, and optimizing our approach to committee engagement so that the experience of serving will be even more meaningful.

Our focus on creating a premier member experience is one of the central components of the IASLC's strategic planning process. This reorganization effort began approximately two years ago. It lays out a roadmap that aims to advance our leadership in the field and shows how we will explore new avenues of interest for our members. In 2019, that will involve us continuing our core activities, while simultaneously creating a new initiative in early screening and detection, beginning work on the ninth edition of the TNM lung cancer staging system and adding an important scientific meeting focusing exclusively on mesothelioma.

The IASLC has a rich history and has acted as a partner and a resource for the lung cancer community for nearly 45 years. Bolstered by the seismic advances occurring in the field, as well as the changes and investments the association is making internally, the IASLC is better positioned than ever to meet the needs of the researchers, clinicians, advocates and patients we serve. And as we move forward together, we commit ourselves to honoring the past, seizing the opportunities of the present and proactively planning for the benefit of our collective future.



Giorgio V. Scagliotti, MD, PhD
IASLC President



Dave Mesko, MBA
IASLC Chief Executive Officer



IASLC 2018 World Conference on Lung Cancer co-presidents Andrea Beziak, Natasha Leighl & Gail Darling; honorary chair Frances Shepherd.

TABLE OF CONTENTS

Member Experience	8
Education	10
Research	22
Scientific Initiatives	24
Publications	28
Journal of Thoracic Oncology	30
Award Winners	32
Patient Advocacy	34
IASLC Essentials	38
Our Sponsors	40
IASLC Foundation	42

www.iaslc.org

CONNECT WITH US

 @IASLC

 facebook.com/IASLC

 linkedin.com

 iaslc.lung

 IASLC

WE ARE THE IASLC.



A Dedicated Global Organization

The IASLC is the only global organization solely dedicated to the study of lung cancer and other thoracic malignancies. Since 1974, the IASLC has promoted research into all aspects of lung and thoracic cancers, while encouraging worldwide prevention efforts.

MEMBERS INNOVATE TOGETHER


From the United States and the United Kingdom to Brazil and Ecuador, from Nigeria and Morocco to Indonesia and Iran, from China and South Korea to the Netherlands and Poland, the IASLC is 6,500 multidisciplinary lung cancer specialists from more than 100 countries. Our diverse membership is united in one goal: to conquer lung and other thoracic cancers worldwide. Our members get closer to that goal each day by collaborating globally and sharing their expertise and scientific findings.

IASLC educational events provide members with access to the latest groundbreaking research, helping them keep pace with the rapidly changing lung cancer field and allowing them to apply this knowledge in their practices. By offering professional and personal development opportunities, the IASLC also provides its members with pathways to advance in their profession and grow in their areas of interest. Extensive networking, mentoring and leadership opportunities set the association apart by delivering significant value to its members.

Member benefits:

- › Access to the *Journal of Thoracic Oncology*, the premier journal in thoracic malignancies
- › Multidisciplinary educational opportunities
- › Discounted registration to meetings, including the annual World Conference on Lung Cancer
- › Worldwide networking, mentoring and collaboration
- › Eligibility for travel awards, committee participation and voting

To encourage multidisciplinary and geographic diversity, the IASLC offers special membership rates for advocates, nurses and allied health professionals, and for residents of developing countries. Fellow, student, resident and trainee, as well as patient/survivor and caregiver memberships, are complimentary.






6,497
MEMBERS
STRONG

FEMALE
35%

MALE
64%

UNKNOWN
1%

Top 10 Countries for Membership:



EDUCATION

The IASLC membership recognizes the importance of staying current on the latest scientific advances and understands how these efforts translate to providing better patient care. That's why, as a member-based organization, the IASLC places an emphasis on creating forums for lifelong learning and professional growth, while fostering member collaboration, networking and relationship-building.

With expert-driven, multidisciplinary content and an international scope, the IASLC's educational offerings cover all aspects of lung cancers and thoracic malignancy management. Our annual World Conference on Lung Cancer, regional conferences, extensive webinar series, hands-on workshops and live-learning events serve as catalysts for the exchange of scientific research advances and clinical experiences among colleagues from all over the world.

The IASLC also employs multimedia learning strategies and provides resources to help members enhance their expertise by publishing textbooks, atlases, staging manuals, patient education materials and web-based tools.

2018 IASLC Educational Events

Fifth AACR-IASLC International Joint Conference on Lung Cancer Translational Science: From the Bench to the Clinic	January 8-11, 2018	San Diego, California, USA
IASLC 18th Lung Cancer Targeted Therapies Meeting	February 21-24, 2018	Santa Monica, California, USA
IASLC-FDA Lung Cancer Neoadjuvant Meeting	March 1-2, 2018	Rockville, Maryland, USA
IASLC Lung Cancer Immunotherapy Meeting	March 22-24, 2018	Madrid, Spain
European Lung Cancer Congress	April 11-14, 2018	Geneva, Switzerland
IASLC Africa Conference on Lung Cancer 2018	April 29-May 1, 2018	Tangier, Morocco
IASLC Latin America Conference on Lung Cancer 2018	August 15-18, 2018	Cordoba, Argentina
IASLC 2018 World Conference on Lung Cancer	September 23-26, 2018	Toronto, Ontario, Canada
IASLC Asia Conference on Lung Cancer 2018	November 7-10, 2018	Guangzhou, China



THE IASLC 2018 WORLD CONFERENCE ON LUNG CANCER

Each year, thousands of attendees from every corner of the globe come together to discuss the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management at the annual IASLC World Conference on Lung Cancer, the association's cornerstone event.

At the 2018 IASLC World Conference on Lung Cancer (WCLC) in Toronto, Canada, over the course of four days, attendees were treated to a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies and liquid biopsy to tobacco control, patient advocacy, immunotherapy and imaging.


Multidisciplinary educational sessions were developed to meet the expectations of the broad range of international delegates, with more than 500 global experts as invited speakers and over 2,000 abstract presentations. Other sessions included thought-provoking keynotes, expert panel discussions with lively debates, interactive grand rounds, informative hands-on workshops and stimulating dialogue based on 1,450 posters.

IASLC members presented groundbreaking results from practice-changing clinical trials at the Presidential Symposium, resulting in four simultaneous publications in the *New England Journal of Medicine*.

Finally, with a steadfast focus on patient advocacy, one plenary session, entitled "**Patients First**," shared stories of hope from patients, caregivers and lung cancer experts, and considered new paths forward.



Patient advocate Lucy Kalanithi spoke at the "Patients First" plenary session.




Stephen Liu presented the results of IMPower133 clinical trial at the Presidential Symposium.



WCLC 2018 AT A GLANCE

ATTENDEES' PRIMARY SPECIALTY



MOST EVER!
7,443
 DELEGATES FROM
96
 COUNTRIES

FIRST TIME ATTENDEES:
34%

ABSTRACTS SUBMITTED:
2,005

559
 INVITED SPEAKERS
 FROM
33
 COUNTRIES

28 PLENARY
 SPEAKERS

433
 ORAL & MINI ORAL
 ABSTRACT SESSIONS

POSTER PRESENTATIONS:
1,450

12,480
 MINUTES OF
 EDUCATIONAL CONTENT

1,329
 CME CERTIFICATES
 REQUESTED

68
 TRAVEL AWARD,
 MENTORSHIP AND
 ACADEMY PROGRAM
 WINNERS FROM

30
 COUNTRIES

TWITTER USERS SENT
11,500+
 TWEETS USING #WCLC2018

36.3
 MILLION
 HASHTAG
 IMPRESSIONS

MEDIA MENTIONS:
9,000+

MEDIA COVERAGE IN
50+
 COUNTRIES

“ Being a mentor provides a tremendous opportunity to learn about the challenges faced by oncologists in other countries. The IASLC should be commended for having a program like this as it benefits both mentor and mentee.”

Charles Butts, MD, FRCP (Mentor)
Cross Cancer Institute, Edmonton, Alberta, Canada

EDUCATIONAL PROGRAMS WORLD CONFERENCE ON LUNG CANCER

International Mentorship Program

Celebrating its fourth year in 2018, the IASLC International Mentorship Program further solidified the IASLC's commitment to educating the next generation of lung cancer researchers. This rewarding program provides positive returns for both mentor and mentee, with the ultimate goal of forging lifelong collaboration.

To apply for the program, candidates submit an abstract for presentation at the IASLC World Conference on Lung Cancer (WCLC) and provide a personal statement on their career goals, describing how the award will assist them.

In 2018, the IASLC Career Development and Fellowship Committee reviewed more than 40 applications and selected 13 recipients. A Nursing and Allied Health Professional mentorship was added in 2018. Program participants were then matched with well-established scientific and clinical mentors from hospitals and research facilities in the region where the WCLC took place.

The awardees met daily with their mentors during the WCLC to discuss relevant conference presentations and strategies for getting the most out of the event. During the week following the conference, the mentees traveled to their mentors' institutions to shadow their mentor, discuss their career path and interact with researchers, physicians and other members of multidisciplinary cancer care teams.

The 2018 mentees were from Argentina, Canada, China, India, Thailand, Turkey, Serbia and Uganda, and their disciplines included basic sciences/cancer research; medical, radiation and surgical oncology; pulmonology; pathology; radiation therapy; and thoracic surgery.

“ You should move out of your comfort zone. If you do, you will always be learning. Go see other places and bring those ideas back to your country and patients. The mentorship program helped me do better for my patients.”

Kuruswamy Prasad, MD, PhD (Mentee)
Postgraduate Institute of Medical Education and Research,
Chandigarh, India



Conquering Thoracic Cancers Worldwide

#WCLC2018



IASLC Academy Program

This innovative program is designed to educate and ensure success for early career thoracic specialists and promote the multidisciplinary management of thoracic malignancies.

Launched at the IASLC 2017 World Conference on Lung Cancer (WCLC), this early career program is open to medical school graduates who have experience working as medical oncologists, radiation oncologists, pulmonologists, thoracic surgeons, pathologists or radiologists.

The unique structure is designed to provide continual guidance to participants throughout its two-year span and beyond. Academy members team up with senior multidisciplinary faculty from around the world.

Members attended two World Conferences on Lung Cancer where they honed their presentation skills in an interactive communications workshop, deepened their research knowledge with world-renowned scientists from academia and industry, and practiced scenarios interacting with specialists on a multidisciplinary cancer care team.

The inaugural class (2017–2018) consisted of 13 physicians from Australia, Canada, Egypt, Italy, Nepal, Portugal, Singapore and the United States.

“For someone like me from Nepal, it would have been impossible to work with such a diverse group of colleagues and interact with leading experts in the field without a program like this.”

*Deebya Mishra, MD
B.P. Koirala Institute of Health Sciences, Dharan, Nepal*



“The IASLC Academy provides a unique opportunity to facilitate networking and collaboration amongst early career physicians from all over the world and international faculty. Its results-oriented structure and the personalized career development guidance provided by faculty members ensure the program’s success.”

*Christian Rolfo, MD, PhD, MBA
University of Maryland, Greenebaum Comprehensive Cancer Center
Maryland, USA*



2018 WORLD CONFERENCE ON LUNG CANCER


Travel Awards

The IASLC offers a variety of travel awards to help researchers from around the world attend the annual IASLC World Conference on Lung Cancer (WCLC). Applications are accepted each year, and the winners are determined by an international multidisciplinary review committee of IASLC members. In 2018, the IASLC provided Developing Nation Awards to 10 researchers from eight countries. Developing nations are defined by IASLC guidelines. The IASLC also granted Young Investigator Awards to 11 researchers from eight countries. Young investigators are defined as 35 years or younger. The IASLC recently expanded its travel program to include two dedicated awards for the Nursing and Allied Health fields. And finally, the IASLC provided travel awards to five Patient Advocates (see p. 37 for more information).

Each award winner submitted an abstract that was chosen for presentation at the WCLC. They worked on the research with a senior author who is an IASLC member. The award includes conference registration, hotel accommodation, travel expenses and a one-year IASLC membership.

Researchers from the following countries received Developing Nation Awards: Brazil, China, Cuba, India, Nigeria, Pakistan, Serbia and Ukraine. Those receiving Young Investigator Awards hailed from China, Italy, Mexico, Netherlands, Pakistan, Spain, United Kingdom and the United States. Finally, researchers from Brazil and Romania received Nursing and Allied Health Travel Awards.

Countries Represented:



“Networking with colleagues means that common challenges can be identified and solutions shared. I am eager to gain new experiences, improve my skills and broaden my understanding of lung cancer and I believe that attending the WCLC will contribute to my learning in the best possible way.”

*Arooj Fatima, MD, Pakistan
Winner of a Young Investigator Travel Award*



“ This organization really knows how to tap into each specialist and draw out the best ideas. Everybody has a voice. Nurses are incorporated into so many of the talks that I’ve been to and they want your opinions. I go home with a wealth of knowledge and resources that I can apply. The IASLC encourages nurses to step up and join the organization.”



Lavinia Dobre, Nurse, USA



“ I’m actively working with key stakeholders – doctors, industry, the FDA and policymakers – to change the present and future for lung cancer patients in India. The WCLC is an opportunity to connect with other groups and learn how to implement initiatives in India.”



Vivek Tomar, Patient Advocate & Caregiver, India

“ As a Latina in medicine, you can feel alone; we are only 1.8% of physicians in the United States. But, at the WCLC, I had the opportunity to meet and network with medical oncologists, radiation oncologists and surgeons from Spain and Latin America. I no longer feel alone because I can see leaders like [IASLC board member] Dr. Enriqueta Felip making a difference in the world of lung cancer.”




Narjast Duma, Hematology-Oncology Fellow, USA & Venezuela

2018 WORLD CONFERENCE ON LUNG CANCER

HONORING THE PAST

The first IASLC World Conference on Lung Cancer was held in 1978 in Hilton Head, South Carolina, USA, and drew 106 participants from 16 countries.



IASLC INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
IASLC 19th World Conference on Lung Cancer
 September 23-26, 2018 Toronto, Canada

TAKE ACTION
 Against Lung Cancer!

FUTURE IASLC WORLD CONFERENCES

IASLC 2019 World Conference on Lung Cancer
September 7-10, 2019
Barcelona, Spain



IASLC 2020 World Conference on Lung Cancer
August 9-12, 2020
Singapore



IASLC 2021 World Conference on Lung Cancer
September 10-13, 2021
Denver, Colorado, USA



2019 Educational Events

IASLC 2019 Targeted Therapies in Lung Cancer Meeting	February 20-23, 2019	Santa Monica, California, USA
IASLC 2019 Small Cell Lung Cancer Meeting	April 3-5, 2019	New York, New York, USA
European Lung Cancer Congress	April 10-13, 2019	Geneva, Switzerland
IASLC 2019 Mesothelioma Meeting	July 10-12, 2019	New York, New York, USA
IASLC 2019 World Conference on Lung Cancer	September 7-10, 2019	Barcelona, Spain
IASLC 2019 North America Conference on Lung Cancer	October 10-12, 2019	Chicago, Illinois, USA
IASLC 2019 Latin America Conference on Lung Cancer	October 17-19, 2019	Mexico City, Mexico

HONORING THE PAST

Developments in molecular biology in the 1980s and 1990s led to the discovery of molecular targets in lung and other cancers, making it possible to inhibit cancer growth by targeting specific genetic mutations. The IASLC held its first Targeted Therapies in Lung Cancer workshop in Marbella, Spain, in 2003. A few years later, it became an annual event.



HONORING THE PAST

The IASLC World Conference on Lung Cancer has been held 19 times in 11 countries on four continents. The following countries have hosted the event: Australia, Austria, Canada, Denmark, Ireland, Japan, Netherlands, South Korea, Spain, Switzerland and the United States. As of 2018, four countries have hosted more than once: Australia, Canada, Japan and the United States.



WEBINARS

In 2018, the IASLC held **25 webinars** with more than **2,000 total participants**. The diverse international faculty hailed from **10** different countries in **Asia**, **Europe** and **North America**.

Topics included:

- › Biomarker directed therapy for small cell lung cancer
- › EGFR-mutant lung cancer
- › Genomic analysis of plasma-free DNA
- › Liquid biopsy for non-small cell lung cancer
- › Mesothelioma
- › Molecular testing
- › Neoadjuvant studies in lung cancer
- › Novel approaches to non-small cell lung cancer
- › Radiotherapy
- › Squamous cell lung cancer
- › Stereotactic Body Radiation Therapy
- › Thymoma





IASLC LUNG CANCER NEWS

Launched in 2016, the *IASLC Lung Cancer News* is the IASLC's bi-monthly educational newspaper. Aimed at addressing the complex intersection of diagnostics, screening, tobacco control, therapeutic intervention and survivorship that is at the heart of thoracic malignancy research, the *Lung Cancer News* aspires to present the most recent, noteworthy lung cancer-related information to a worldwide audience while also facilitating the professional development of those working in lung cancer.

IASLC CONNECT NEWSLETTER

The IASLC's newest communications tool, IASLC Connect, is a monthly email newsletter designed to keep members and other interested parties up-to-date on the latest association happenings, upcoming events, member news, fellowship and research funding, progress and trends in the field of thoracic cancers, and more.

IASLC
INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Connect

CONQUERING THORACIC CANCERS WORLDWIDE

JANUARY 2019




Discover how the IASLC and its global membership are working hard to conquer thoracic cancers worldwide.

[EVENTS](#) | [WEBINARS](#) | [FUNDING OPPORTUNITIES](#) | [JTO EDITOR'S CHOICE](#)

President's Corner

In the last newsletter of 2018, I informed you of changes made to the IASLC strategic plan. Now, I can say that transition time is over and all our planned activities for 2019 are in place and new ones are popping up. For instance, I hope you appreciate the refreshed version of the IASLC newsletter, now renamed the "IASLC Connect." Our staff in Denver has reimagined the newsletter's design and purpose, transforming it into a concise, relevant and highly member-focused piece of content. In future months, we will ideally transition to including more video rather than text. I hope you will enjoy [Read more.](#)



V3 / N4 / AUGUST 2018

FOR THORACIC SPECIALISTS

Read online at
LungCancerNews.org &
Visit IASLC.org



LUNG CANCER NEWS

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

INSIDE

6 KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1-Positive Disease

7 Circulating Tumor Cell-Derived Patient eXplants: A New Tool for SCLC Research

IMMUNOTHERAPY

Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care

By Kara Nyberg, PhD

Treatment advances for metastatic squamous cell carcinoma have long lagged

KEYNOTE-407: New Standard

The global phase III KEYNOTE-407 trial included 559 patients with squamous NSCLC without regard to tumor PD-L1

of carboplatin and paclitaxel or nab-paclitaxel, plus either pembrolizumab or placebo. Maintenance pembrolizumab or placebo was administered in accord with


RESEARCH

Research is a cornerstone of the IASLC. The IASLC Foundation supports the next generation of lung cancer researchers by providing fellowships and grants to the best and brightest physicians, scientists and other health professionals throughout the world.

IASLC research is made possible by the tremendous generosity of members, donors and corporate and nonprofit partners. Since 1999, **114 fellowships** and grants worth **\$5 million** have been awarded to researchers in **33 countries**.

Lung cancer is a complex disease. A continually evolving understanding of the disease at every stage can help patients and caregivers navigate treatment options.

**RESEARCH HELPS
US BETTER
UNDERSTAND.**



2018 RESEARCH AWARD WINNERS

IASLC FOUNDATION FELLOWSHIPS

Anastasios Dimou, MD
University of Colorado
USA

Laura Mezquita, MD, PhD
Institut Gustave Roussy
France

Sanghyuk Song, MD
Kangwon National University Hospital
South Korea

IASLC FOUNDATION YOUNG INVESTIGATOR AWARDS

Benjamin Lok, MD
Princess Margaret Cancer Centre
Canada

John Charles Rotondo, PhD
University of Ferrara
Italy

Aaron Tan, PhD
National Cancer Centre
Singapore

IASLC JOINT RESEARCH AWARDS

Prevent Cancer Foundation/IASLC Foundation Lung Cancer Fellowship

Atiqur Rahman, PhD
University of Newcastle
Australia

Lung Cancer Foundation of America/IASLC Foundation Lori Monroe Scholarship in Translational Lung Cancer Research

Alice Berger, PhD
University of Washington
USA

Christine Lovly, MD, PhD
Vanderbilt University School of Medicine
USA

Lung Cancer Foundation of America/Bristol-Myers Squibb/IASLC Foundation Young Investigator Award

Kathryn Beckermann, MD, PhD
Vanderbilt University School of Medicine
USA

Zoltan Lohinai, MD, PhD
National Koranyi Institute of Pulmonology
Hungary

Free ME from Lung Cancer/IASLC Foundation Joint Fellowship Award for the Early Detection of Lung Cancer

Eva Koziolk, PhD
University of California Los Angeles
USA

“The support of the IASLC has allowed me to pursue an ambitious genome sequencing project. It is allowing our lab to launch a unique collaboration with the Women’s Health Initiative to better understand the genomic features of lung cancer in women who have never smoked. Previous genome studies either include a small number of never-smokers or do not sequence the entire genome, meaning that we have probably missed many important mutations that contribute to disease in never-smokers and that might be targeted for therapeutic benefit.”

Alice Berger, PhD, USA
2018 LCFA/IASLC research award recipient




“The IASLC Young Investigator Award has clearly enhanced my academic career. To be the recipient of this prestigious international award has opened new doors and opportunities for me. This award also gives me added confidence to continue on my mission to make strides for our lung cancer patients. It gives me great pride, joy and purpose to work alongside the dedicated members of the IASLC and the organization itself to fulfill this worthy mission.”

Benjamin Lok, MD, Canada
2018 IASLC Foundation Young Investigator Award recipient



SCIENTIFIC INITIATIVES



BLUEPRINT PROJECT CONTINUES TO DEMONSTRATE PROGRESS

While developments in lung cancer immunotherapy continue to show promise, PD-L1 protein expression, a tumor biomarker, can help doctors surmise which patients are more likely to respond. But evaluating PD-L1 status remains a clinical challenge, and patient selection is paramount, as only about 20 to 30 percent of patients with advanced non-small cell lung cancer will benefit from immunotherapy.

A PD-L1 test involves sending a piece of tumor tissue to a lab for analysis and helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors. With clinicians using various assessments, or assays, to detect PD-L1, confusion remains regarding the interchangeability, as each was developed as a predictive biomarker for its respective immunotherapeutic.

To address this question, the IASLC Pathology Panel, together with industry partners, launched a clinical and analytical comparative study of the performance of the various assays beginning in 2016. In 2018, Blueprint entered Phase IIb. Researchers used PD-L1 scores to compare the three predictive assays, but in this phase, used large tumor resection blocks, small biopsy samples and fine needle aspirate cell blocks prepared from the same tumor.

The result? The Blueprint Project series has provided assay comparability data for clinical use of PD-L1 testing. Blueprint Phase IIb largely reaffirms the earlier data around assay performance and inter-observer variability. Finally, matched samples (fine-needle aspirate, biopsy, large block) from the same tumor show good comparability between the tumor proportion scores (the percentage of viable tumor cells showing partial or complete membrane staining).




PREPARING FOR THE NINTH EDITION OF THE TNM STAGING SYSTEM

For the past two decades, the IASLC's Staging and Prognostic Factors Committee (SPFC) has investigated and improved the Tumor Node Metastasis (TNM) system for lung, mesothelioma, esophageal and thymic tumors. The IASLC staging project has provided evidence-based recommendations to governing organizations. These collaborative efforts have enhanced the TNM system and improved overall patient care worldwide.

In 2018, the SPFC began working toward the development of its recommendations for the ninth edition of the TNM Classification, scheduled to be published in 2024. As part of this effort, the SPFC launched an international call for data contribution, which is crucial for the development of the upcoming edition.

The ninth edition will incorporate anatomical data as well as molecular mutations. These additions will improve prognosis and lead to better personalized therapy for patients.

With the help of the international community, the IASLC staging project will continue to guide cancer care teams and treatment strategies while offering opportunities to collaborate with colleagues and share patient outcomes.



THE IASLC AIMS TO INCREASE EARLY DETECTION OF LUNG CANCER


Early detection is the key to curing or successfully managing many cancers. For lung cancer, low-dose computed tomography (LDCT) screening can decrease mortality by 20 to 61 percent among high-risk populations, such as former and current smokers. Unfortunately, only two percent of the patients eligible for screening in the United States were tested in 2016. A possible roadblock to these screenings is the lack of available tools for the health care provider to evaluate lung LDCT images.

In an effort to improve early detection, the IASLC created the Early Lung Imaging Confederation (ELIC). From this pilot project came a beta version of a secure, globally-accessible software that can collect and analyze CT images and biomedical data from around the world.

Working with international investigators and clinicians, the IASLC is building a repository of de-identified CT images and data, which are then populated into spoke servers in various countries. Unveiled at the 2018 World Conference on Lung Cancer in Toronto, the ELIC pilot demonstration ran on a central digital hub with 10 spoke servers and showed that ELIC can analyze collections of globally-distributed images and data.

ELIC stands to become an important global resource for lung cancer researchers and care teams. The collection of images and data have the potential to help build better analysis and detection tools and create better risk models, as well as being a global platform for standardized data and quality conformance. By collecting these images across institutions and throughout the world, researchers who might only have access to a small number of CT images in their centers can examine thousands of images and utilize software analysis tools to greatly expand their knowledge base.

As the IASLC moves forward with the ELIC project, the association will continue to demonstrate what global collaboration, cutting edge science and technological advancement can achieve.



THE ROLE OF NEOADJUVANT THERAPY IN LUNG CANCER

For years, cancer care teams have chosen to implement neoadjuvant therapy, or delivery of a therapy before the main treatment, which most often is surgery. However, the role of immunotherapy and targeted therapy in the neoadjuvant context has yet to be defined in lung cancer. With the success of these regimens for advanced stage patients, there is now a renewed interest in studying these potentially powerful therapies in the neoadjuvant setting.

In March 2018, the IASLC and the U.S. Food and Drug Administration (FDA) held a workshop for multidisciplinary experts to discuss neoadjuvant strategies, new modalities, lessons learned from neoadjuvant efforts in other cancers and standardization of trial design and outcomes. By uniting key stakeholders involved in clinical research and trial design, the IASLC and the FDA aimed to leverage their collective expertise to improve patient care and expedite drug development for patients with lung cancer.

The joint workshop resulted in a published review article in the IASLC's *Journal of Thoracic Oncology*, providing guidance on the standardization of pathological evaluation and outlining best practices for lung cancer trials. The article discusses everything from the advantages of neoadjuvant therapy and suggested imaging techniques to pathologic response assessments and surgical considerations. Ultimately, the attendees concluded that neoadjuvant therapy provides unique opportunities to enhance curability and accelerate the development of new agents for lung cancer.

2018 PUBLICATIONS

CONSENSUS REPORTS, GUIDELINES AND STATEMENTS

Best Practices for Diagnostic Immunohistochemistry


Since the release of the 2015 World Health Organization Classification of Lung Tumors, immunohistochemistry (IHC) has figured prominently in lung cancer diagnoses. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. After receiving questions on practical application and interpretation of IHC in lung cancer diagnoses, the IASLC Pathology Committee summarized best practice recommendations for diagnostic IHC in lung cancer, addressing key issues and covering common diagnostic situations in daily clinical practice in 2018. The article provides answers to key questions about the use of IHC in lung cancer diagnoses, representing viewpoints of thoracic pathology experts that can help practitioners appropriately use IHC in diagnostic pathology.

Statement: Cancer Screening with Low-Dose Computed Tomography

In 2018, the IASLC Prevention, Screening and Early Detection Committee issued a statement encouraging international leaders, governments, health care systems and other stakeholders to implement global lung cancer screening programs with low-dose computed tomography (LDCT). The recommendation is based on evidence arising from two randomized trials affirming that LDCT screening in high-risk individuals can significantly reduce lung cancer mortality. Due to current challenges in lung cancer screening, including lack of familiarity about the needs for LDCT by the primary care community and limitations with national health policies and systems, the IASLC plans to serve as a resource to help with global implementation of these screening services.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)

The IASLC convened a multidisciplinary panel of thoracic oncology experts in 2018 to create recommendations for using liquid biopsy for molecular analysis to guide the clinical management of non-small cell lung cancer (NSCLC). Liquid biopsy, which utilizes blood instead of tumor samples, is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types. Recently, an increasing number of innovative platforms have been developed that improve not only the reliability of the molecular analysis, but also the number of tests performed on a single sample. The IASLC released a statement paper concluding that liquid biopsy has significant potential to improve patient care and recommended immediate implementation in a number of therapeutic settings relevant to NSCLC.



A woman with dark hair pulled back, wearing a white lab coat over a light green top, is looking down at a document she is holding. She is in a laboratory or office setting with a microscope and other equipment visible in the background. The lighting is warm and soft.

Consensus Report: Current and Future Management of Mesothelioma

The IASLC Mesothelioma Task Force, together with the National Cancer Institute (NCI) Thoracic Malignancy Steering Committee and the Mesothelioma Applied Research Foundation, published a 2018 consensus report on the current and future management of mesothelioma. The paper grew out of the 2017 Mesothelioma Clinical Trials Planning Meeting, which brought together leading academicians, clinicians, scientists and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients diagnosed with malignant pleural mesothelioma. Considering the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the meeting attendees aimed to create a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.

Molecular Testing Guideline

Three leading medical societies – the College of American Pathologists (CAP), the IASLC and the Association for Molecular Pathology (AMP) – released their updated evidence-based guideline for molecular testing in lung cancer in 2018.



The *Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors* strengthens or reaffirms the majority of the 2013 recommendations for patients with lung adenocarcinoma while also recommending testing on some new genes. Identifying patients whose tumors harbor specific molecular alternations leads to more personalized treatment, which may improve survival and quality of life.

THE JOURNAL OF THORACIC ONCOLOGY (JTO)

The *Journal of Thoracic Oncology* (JTO), the IASLC’s official journal, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. The JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians and research scientists with a special interest in thoracic oncology.

The 2017 Impact Factor was 10.336, up from 6.595 in 2016. The JTO ranked 11th out of 222 for oncology and fourth out of 59 for respiratory system subject matter categories in the 2017 Journal Citation Reports.


Promotion by the IASLC and JTO authors was expanded during 2018. The IASLC distributed multiple social media posts and select press releases of JTO articles. Authors could promote their own work via a personal article link for their published articles. This link provides free access to an article for 50 days. It also allows authors to email the link to co-authors and colleagues and post the link on personal webpages and social media.




Journal of Thoracic Oncology

Volume 13, Number 1, January 2018

Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief



Conquering Thoracic Cancers Worldwide
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER



IASLC 2018 AWARD WINNERS

Distinguished Award Winners

These prestigious, long-standing awards recognize lifetime achievement in specific areas of lung cancer research. Each scientist received their award at the opening ceremony of the IASLC 2018 World Conference on Lung Cancer.

PAUL A. BUNN, JR. SCIENTIFIC AWARD



Charles Swanton, PhD, FRCP, United Kingdom

Director, CRUK Lung Cancer Centre of Excellence
Senior Group Leader, The Francis Crick Institute,
London, UK

JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD



Fadlo Khuri, MD, FACP, Lebanon

President, American University of Beirut, Lebanon
Professor, Department of Hematology and Medical
Oncology, Emory University School of Medicine,
Atlanta, Georgia, USA



Nise Yamaguchi, MD, PhD, Brazil

Clinical Director, Instituto Avancos de Medicina,
Sao Paulo, Brazil
Senior Scientist, International Prevention
Research Institute, Lyon, France
Co-founder, World Cancer Alliance, Lyon, France

MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD



Ignacio Wistuba, MD, USA

Chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine and Professor,
Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

MERIT AWARD



Françoise Mornex, MD, PhD, France

Professor, Oncology, University Claude Bernard, Lyon, France
Past Chair, Radiation Oncology Department, Centre Hospitalier Lyon-Sud, France

Lectureship Award Winners

At the IASLC 2018 World Conference on Lung Cancer, leaders in the field were invited to give a lecture on their discipline.

Adi F. Gazdar Lectureship Award for Translational Research

Matthew Meyerson, MD, PhD, USA

Lecture title: Genomic Alterations in Human Lung Cancers

Robert J. Ginsberg Lectureship Award for Surgery

Valerie W. Rusch, MD, FACS, USA

Lecture title: Honoring the Tradition of Surgically-Based Clinical Trials

Heine H. Hansen Lectureship Award for Small Cell Lung Cancer

Charles M. Rudin, MD, PhD, USA

Lecture title: New Opportunities in Small Cell Lung Cancer

Daniel C. Idhe Lectureship Award for Medical Oncology

David P. Carbone, MD, PhD, USA

Lecture title: The Intersection of Science and Medicine

Clifton F. Mountain Lectureship Award for Staging

Johan Vansteenkiste, MD, PhD, Belgium

Lecture title: Is There Still a Stage for Improvements in Staging?

Tsuguo Naruke Lectureship Award for Surgery

Hisao Asamura, MD, Japan

Lecture title: The Value of the Naruke Lymph Node Chart

IASLC Lectureship Award for Nursing and Allied Health

Kimberly Rohan, APN, USA

Lecture title: The Right Hand - The Art of Collaboration

IASLC Lectureship Award for Radiation Oncology

Hak Choy, MD, USA

Lecture title: Defining the Role of Radiotherapy for Lung Cancer - Past, Present and Future

Cancer Care Team Award

The IASLC introduced the Cancer Care Team Award in 2017 with the goal of recognizing multidisciplinary teams providing outstanding lung cancer patient care throughout the world. What makes the award unique is that care teams are nominated by patients and/or advocates.

More than 60 entries were evaluated by an international multidisciplinary panel. A finalist was selected from each region, and from those finalists, an overall winner was chosen. A team of physicians, nurses and allied health professionals from **Nucleo de Oncologia da Bahia in Brazil** received their award during the IASLC 2018 World Conference on Lung Cancer.



PATIENT ADVOCACY

Patient advocacy is an emergent area for the IASLC. With the goal of promoting, facilitating and supporting successful interaction between patients, advocates, physicians and researchers, the IASLC's role in patient advocacy has grown steadily each year since 2013.

With a steadfast focus on increasing the presence, expertise and participation of patients/survivors and advocates on a global level, the IASLC provided assistance in 2018 for advocates to travel to key conferences and events, including the IASLC World Conference on Lung Cancer in Toronto and the Lung Cancer SPORE workshop at UT Southwestern in Dallas, Texas, USA.

“I can't even describe how much I learned and how valuable this knowledge and networking opportunity is to my work as a lung cancer patient advocate. The more I know, the better I can understand the concepts coming forward and provide relevant and meaningful patient-focused comments and feedback.”

*Judy Johnson, Patient Advocate, USA,
who received assistance from the IASLC
to attend the Lung Cancer SPORE workshop*

Lung Cancer Awareness Month

Lung Cancer Awareness Month (LCAM) began in 1995 as a day of recognition and has grown into a month-long, worldwide initiative designed to highlight the leading cause of cancer death globally. Since 2016, the IASLC has facilitated LCAM through the Lung Cancer Awareness Month Coalition, an international group of research and advocacy organizations working to improve outcomes for lung cancer patients across the globe. By raising awareness of the disease each November, the Coalition aims to increase research funding, improve patient care and reduce mortality.


The Coalition's main objectives are to educate patients/survivors, caregivers and care teams on a global level and to reduce mortality by communicating scientific research advancements.

In 2018, worldwide participation increased, with Coalition membership growing to 39 leading research and advocacy organizations from all corners of the world. The joint public awareness campaign, which all Coalition partners supported, included educating the public on four main focus areas:


- › Screening and early detection
- › Clinical trials
- › Precision medicine
- › Advocacy

To that end, the Coalition produced patient-provider cards. These handy, colorful and engaging resources are designed to provide patients and their providers with introductory information to promote further discussion, prompt supplemental research and enable informed choices regarding care plans.

The patient-provider cards are downloadable in seven languages. More information on LCAM and the patient-provider cards can be found at LCAM.org.



LUNG CANCER AWARENESS MONTH 2018 SPONSORS



Bristol-Myers Squibb

Lilly | ONCOLOGY



Genentech
A Member of the Roche Group

AstraZeneca  **NOVARTIS** **AMGEN**

Takeda **abbvie**
ONCOLOGY

The image shows several overlapping brochures with a blue and orange color scheme. The brochures contain various pieces of information:

- Top-left brochure:** "As a healthcare provider, you are in a unique position to change the landscape for lung cancer." It features an icon of a head with a heart and a brain.
- Second brochure from left:** "Should I talk to my doctor about clinical trials?" It features an icon of a magnifying glass over test tubes.
- Third brochure from left:** "What's going on in my chest? Early detection is key." It features an icon of an alarm clock and lungs.
- Fourth brochure from left:** "Precision medicine is now a powerful way of treating lung cancer, offering a new opportunity for benefit and survival." It features an icon of a DNA helix and lungs.
- Fifth brochure from left:** "Is your tumor being tested?" It features an icon of a clipboard with a checklist.


Visible text on the brochures includes:

- "Your voice is equally important to the patients and will help people change their old view of lung cancer and their attitude towards people affected by this disease."
- "1. Increase awareness. Get involved with a local organization to raise awareness and fight the stigma surrounding lung cancer. Lung Cancer Awareness Month every November is a good time to spread the word. Encourage your hospital, university, or practice to feature patient stories, display educational materials, or promote awareness through local media and share information on social media and share information on the hope provided."
- "When it is small and before it has spread, people have a better chance of finding it. Early detection is key. It may not be as easy as coughing, trouble breathing, and wheezing. If you are experiencing any of these symptoms, see your doctor immediately."
- "Clinical trials are a way to help. For clinical trials in initial treatment, you may not always be aware of all the options. Clinical trials may be a way to help. Make sure patients are not excluded from clinical trials in initial treatment from previous treatments."
- "Precision medicine helps doctors learn about the characteristics of a person's tumor. Depending on the results, there are targeted treatments that may be available to customize treatment to each person's tumor. It is important to have your tumor tested."
- "Personalized medicine? Precision medicine helps doctors learn about the characteristics of a person's tumor. Depending on the results, there are targeted treatments that may be available to customize treatment to each person's tumor. It is important to have your tumor tested."

2018 LCAM Partners

- › ALK Positive
- › American Lung Association/ LUNGFORCE
- › American Lung Association Colorado
- › Bonnie J. Addario Lung Cancer Foundation
- › Caring Ambassadors
- › Catch It In Time
- › Chris Draft Family Foundation
- › Citizens for Radioactive Radon Reduction
- › Clifton Mountain Foundation
- › EGFR Resisters
- › Free ME From Lung Cancer
- › Free to Breathe
- › GRACE
- › IASLC
- › IASLC Foundation
- › Israel Lung Cancer Foundation
- › International Thoracic Oncology Nursing Forum (ITONF)
- › LiveLung/Dusty Joy Foundation
- › Lung Cancer Alliance
- › Lung Cancer Europe/WALCE (Italy)
- › Lung Cancer Foundation of America
- › Lung Cancer Initiative of North Carolina
- › Lung Cancer Research Foundation
- › Lung Foundation Australia
- › LUNGevity
- › Marie Keating Foundation (Ireland)
- › Move Against Cancer Africa (Nigeria)
- › National Lung Cancer Forum for Nurses (NLCFN)
- › NEFES (Turkey)
- › Instituto Oncoguia (Brazil)
- › Patient Power
- › Pembe Hanim (Turkey)
- › Polish Lung Cancer Group (Poland)
- › Rexanna Foundation
- › Ride Hard. Breathe Easy.
- › SWOG Cancer Research Network
- › University of Colorado Cancer Center
- › University of Maryland
- › Upstage Lung Cancer

IASLC Foundation board member, patient advocate and lung cancer survivor, Kathy Weber (r), with her family.



“ The IASLC World Conference on Lung Cancer is the spot. The place to be. It gives you a strong message that your work matters. If you are an allied health professional, you know you are supported.”

*Csaba Degi, Psychologist, Social Worker,
Researcher and Advocate, Romania*



Patient Advocacy Travel Awards

Each year the IASLC provides patient advocates with the opportunity to travel to the World Conference on Lung Cancer (WCLC). Designed to increase the connection between the IASLC and the patient advocacy community, individuals (including survivors) and those who work for advocacy organizations, are encouraged to apply for these awards. In 2018, the IASLC awarded five patient advocates from India, Nigeria and the United States. They received conference registration, hotel accommodation, travel expenses and a one-year IASLC membership.



Travel award winners Caleb Egwuenu of Nigeria and Erin Sarauer of the United States at WCLC 2018 in Toronto.



Patient advocates Jill Feldman and Ivy Elkins.



“The IASLC provides a really important opportunity to learn what’s happening in the global community – to know there is a huge community of people who are all working toward the same goal. Early in my career I was the only one at my institution focused in lung cancer and yet I was able to find mentors through the IALSC and those relationships continue today.”



Heather Wakelee, Medical Oncologist, USA

“My favorite part of being an IASLC member is having the ability to stay updated on important advances in lung cancer research through attending conferences and reading articles in the *Journal of Thoracic Oncology*. As a lung cancer survivor, I love that the IASLC offers free conference attendance and a free journal subscription to patients like myself.”

IVY ELKINS, PATIENT ADVOCATE, USA



IASLC ESSENTIALS

The IASLC is governed by a multidisciplinary, geographically diverse board of directors. Supported by a talented staff with an impressive range of professional backgrounds, the IASLC's board members promote ongoing organizational growth through strategic guidance and operational and financial oversight. Elections are held every two years and board terms are for four years.

Together, the IASLC's board and staff are committed to core values of leadership, research, innovation and educational excellence.

The IASLC's worldwide headquarters is located in Denver, Colorado, USA.

THOMAS JOHN, MEDICAL ONCOLOGIST, AUSTRALIA

“The committees are a good way of being involved and of being in contact with a broad group of people from various disciplines. It's very important to have input to the IASLC from representatives from different parts of the globe.”

IASLC BOARD OF DIRECTORS

2018-2019

OFFICERS

President: **Giorgio V. Scagliotti** (Italy)

President-Elect: **Tetsuya Mitsudomi** (Japan)

Past-President: **David P. Carbone** (USA)

Treasurer: **Tony S. Mok** (Hong Kong)

Chief Executive Officer: **Dave Mesko** (USA)

MEMBERS

Michael Boyer (Australia)

Julie Brahmer (USA)

Enriqueta Felip (Spain)

Anne Fraser (New Zealand)

David Harpole (USA)

Norihiko Ikeda (Japan)

Clarissa Mathias (Brazil)

Yuko Nakayama (Japan)

Masayuki Noguchi (Japan)

Robert Pirker (Austria)

Suresh Ramalingam (USA)

Martin Reck (Germany)

Miyako Satouchi (Japan)

Takashi Seto (Japan)

Paul E. Van Schil (Belgium)

Heather Wakelee (USA)

James Yang (Taiwan)

IASLC STAFF

Dave Mesko, Chief Executive Officer
John Skadow, Chief Financial Officer
Julie Bishop, Committee Coordinator
Kirsten Black, Educational Programs Manager
Becky Bunn, Director of Strategic Initiatives
Jill Daigneault, Scientific Affairs Project Manager
Kathy Doherty, Director of Human Resources
AnnMarie Estrada, Senior Director, Corporate Relations; Executive Director, IASLC Foundation
Jennifer Hedger, Scientific Affairs Coordinator
Kristin Ito, Patient Advocacy Manager
Abigail Metzger, Corporate Relations Coordinator
Colleen Miller, Director of Communications and Marketing
Adam Mohrbacher, Communications and Marketing Manager
Karen Muth, Executive Assistant and Board Liaison
Emily Petoskey, Foundation Coordinator
Kristin Richeimer, Senior Director of Membership Experience
Mary Todd, Managing Editor, *Journal of Thoracic Oncology*
Jacinta Wiens, Associate Director of Scientific Affairs
Kelsey Wood, Membership Manager
Murry Wynes, Senior Director of Scientific Affairs
Kexin Yu, Accountant

JOURNAL OF THORACIC ONCOLOGY

Alex A. Adjei, Editor-in-Chief
Mary Todd, Managing Editor

IASLC COMMITTEE LEADERSHIP

IASLC committees assist with the development of new programs and initiatives. Committee members contribute their specialized skills and talents to help influence the work of the organization by developing educational content; shaping the association's messaging; planning global and regional scientific meetings; contributing to publications authored by the IASLC; providing strategic insight; and more.

2018-2019

Advanced Radiation Therapy Committee

Suresh Senan, Chair

Awards Committee

Giorgio Scagliotti, Chair

Bylaws Committee

Philip Bonomi, Chair

Career Development & Fellowship Committee

Leora Horn, Co-chair

Glen Weiss, Co-chair

Communications Committee

Richard Booton, Chair

Continuing Medical Education Committee

Thierry Jahan, Chair

Education Committee

Daniel Tan, Chair

Ethics Committee

Shirish Gadgeel, Chair

Finance Committee

Tony Mok, Chair

Membership Committee

Ray Osarogiagbon, Chair

Nominating Committee

David Carbone, Chair

Nurses and Allied Health Professionals Committee

Pippa Labuc, Chair

Pathology Committee

Ignacio Wistuba, Chair

Patient Advocates Committee

Stefania Vallone, Chair

Prevention, Screening and Early Detection Committee

James Mulshine, Chair

Publications Committee

Edgardo Santos, Chair

Staging and Prognostic Factors Committee

Hisao Asamura, Chair

Strategic Committee

Michael Boyer, Chair

Tobacco Control and Smoking Cessation

Emily Stone, Chair

Mesothelioma Task Force

Michele Carbone, Chair

Quality and Value Task Force

David Gandara, co-chair

Ronan Kelly, co-chair



abbvie

AstraZeneca 



Bristol-Myers Squibb



Boehringer
Ingelheim



Lilly | ONCOLOGY

The IASLC would like to thank its top sponsors for their generous support



Genentech
A Member of the Roche Group

Janssen
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

 **MERCK**

Medscape

 **NOVARTIS**

 **Pfizer Oncology**

 **Roche**

 **Takeda**
ONCOLOGY

IASLC FOUNDATION

Established in 2014, the IASLC Foundation works to accelerate the pace of lung cancer and thoracic malignancy research by assisting the IASLC's efforts toward reducing lung cancer mortality worldwide.

Every dollar donated to the Foundation supports lung cancer research by funding physicians and scientists through fellowships, young investigator awards and partnership grants. The Foundation also recognized outstanding cancer care teams globally by awarding the Cancer Care Team Award.

In 2018, the Foundation awarded 12 fellowships and young investigator grants totaling more than \$1.2 million dollars. To date, the IASLC Foundation has given nearly \$5 million to lung cancer research.


The Foundation has continued to grow, mature and expand. In 2018, the Foundation took steps to transition to a 501(c)(3) public charity. A rebranding effort is underway and will be revealed in late 2019.

In 2018, the Foundation united with like-minded organizations to build partnerships and award joint grants that will yield an even greater impact.



“ The IASLC award has been greatly impactful in my career. It's fueled my research on resistance to targeted therapies among lung cancer patients with activating EGFR mutations. I chose a career in lung cancer research because lung cancer is the leading cause of cancer related deaths, a significant burden for hundreds of thousands of people and their families, and because I believe that the scientific community is on the brink of major advances in the field. **”**

Anastasios Dimou, MD, USA & Greece
2018 IASLC Foundation Fellowship Award recipient



IASLC Foundation Research Awards

APPLICATIONS RECEIVED

2017: **19** 2018: **58**

205%
INCREASE



REWARDING SCIENTIFIC EXCELLENCE

IASLC Foundation Contribution Comparison



TOTAL CONTRIBUTIONS RECEIVED

2017: **\$309,597** 2018: **\$641,320**

107%
INCREASE

BUILDING PARTNERSHIPS

IASLC Foundation Research Awards

TOTAL \$ AWARDED

2017: **\$785,000** 2018: **\$1,037,500**

32%
INCREASE



SAVING LIVES WITH RESEARCH

To date, the IASLC Foundation and the Lung Cancer Foundation of America have partnered to fund nearly \$4 million in research grants.



Adi Gazdar and his wife, Celia, at the IASLC 2018 World Conference on Lung Cancer in Toronto.

Dr. Gazdar was the largest contributor to the IASLC Foundation. In 2013, he donated \$250,000 to strengthen the fellowship program.

“The IASLC research grants that are targeted at people early in their career really do an amazing job of introducing you to so many important people in the field. You get to sit at the table with the smartest people in lung cancer and pick their brain. I think without this grant I was never going to get to that table. I am incredibly grateful for my grant from the IASLC. It did so much for my career.”

*Jessica Donington, Thoracic Surgeon, USA
IASLC research award recipient*



Remembering Dr. Adi Gazdar (1937-2018)

A true giant in the field of lung cancer research, Adi Gazdar was a remarkable friend to the IASLC. He was a groundbreaking pathologist, a cell line pioneer, an inspiring mentor and a brilliant collaborator. An active IASLC member for more than 35 years, Dr. Gazdar served on the board of directors and played a critical role on the IASLC Pathology Committee, helping set the standards for the pathological classification of lung cancers worldwide.

An exceptional mentor, Dr. Gazdar trained hundreds of fellows in lung cancer biology and pathology and touched many others through his work. He was also a generous contributor to the IASLC Foundation – helping ensure the education of the next generation of lung cancer researchers.

The IASLC mourns the loss of this remarkable researcher and honors him for his tremendous contributions both to our organization and to the field of lung cancer. He will be greatly missed.

HONORING THE PAST

The IASLC awarded its first fellowship in 1999. To date, a total of 114 have been granted to promising young research scientists throughout the world.

IASLC FOUNDATION BOARD OF DIRECTORS

2018-2019

OFFICERS

President: **Giorgio V. Scagliotti**

President-Elect:
Tetsuya Mitsudomi

Past-President:
David P. Carbone

Secretary/Chief Executive
Officer: **Dave Mesko**

Treasurer: **Tony S. Mok**

MEMBERS

Marc Braunstein

David R. Gandara

Lauren Fisher

Paolo Paoletti

Bruce Ratner

Kathy Weber

2018 IASLC FOUNDATION DONORS

10,000 +

Adi & Celia Gazdar

\$5,000 - \$9,999

The Chris Draft Family
Foundation

David R. Gandara

Fred & Pia Hirsch

Charles & Jean Townsend

Li Xu

\$1,000 - \$4,999

Marc & Claudia Braunstein

Paul A. Bunn, Jr.

David Paul Carbone

Martin Edelman

David M. Jablons

Thomas Lee

Martha & Gregory Raber

Takashi Seto

Daniel Sipe

Tyson Valdivia

Steven R. and Julie A.
Williams Foundation

James Chih-Hsin Yang

\$500- \$999

Lauren Fisher

Phillippe Laumont

Noor Nagamani

Albert J. Polman

Suresh S. Ramalingam

Kristin Richeimer

Sandeep Sharma

William Travis

Kathy Weber

Up to \$499

Wendy Aaronson

Adejare Samson Adewuyi

Rocky Mountain Adventist

Samuel Aguayo

Farah Ahmed

Stacey Algren

Koami Freitas
Amah-Tchoutchoui

Sita Andarini

Naoko Aragane

Michael Peter Arendse

Linda Ayres

Patricia Backes

Ami Bahde

Sheila Bahlow

Denise Balbier

Bobbi Banchemo

Darrald Barajas

Patricia Benjamin

Peter Berzinec

Rodney Blank

Nicole Bower-DeFee

Carol Brown

Mary Brusca

Melissa Burton

Giovanni Carboni

Ferdinando Cerciello

Oliver Chateau

Beverly Chernaik

Jonathan Cho

Josh Cimala

Rose Marie Cleland

Caryn Cohen

Christopher Todd Collins

Jarod Conley

Babita Das

Luis DaSilva

Marjorie Deninger

Kenneth Derose

Sally Disler

Joyce Divine

John Dougherty

Charles Dougherty

Kevin Downing

Anita Driscoll

Thomas Eads

Green Valley Elementary
School

Yvette Ellis

Martha Engstrom

AnnMarie Estrada

Shixia Feng

Gene Finley

Arlene Fitze

Jim Fitze

Susan Foster

Etsuo Fujita

Lesley-Anne Furlong

Joannis Galanos

Vinod Ganju

Laurie E. Gaspar

Maurice Goodgaine

Michele Gray

Mary Ellen Graziano

Claudia Guerra

Xiangkun Han

Alison Hankins

David M. Hasson

Kimberly Hazuda

David Felix F. Heigener

Heidi Hench

Amanda A. Hess

Teodor Horvath

Mary Lou Hubbard

Linda Huntt

Peter Illei

Dan Heritage Ent. Inc.

Helgi J. Isaksson

Anthony Jarkowski

Jane L. Johnston

Ebenezer Kio

Rhonda L. Kitzler

Trena Knowlton

Michael Koenig

Krassimir Dimitrov Koynov

Corey J. Langer

Dawn Lehman

Jeannie Limpert

Donald Linton

Hongxu Liu

Joe's Upholstery LLC

Priscilla Lyon

Hassen Mahfouf

Krishna Mohan Mallavarapu

Christie Malnati

J. C. Marletto

Burnett McKnight

David Mednick

Andrew Merkle

Dave Mesko

Sebastian Michels

Ami Miller

Michele Mital

The Mitchell Family

Anthony Morse

Gretchen Muehlnickel

Deborah Neveleff

Dennis Newberry

Susan Newberry

Marty Olson

James Osborne

Sezin Palmer

Jennifer M. Patterson

Emily Petoskey

Xiusong Qiu

Faisal Qureshi

Sengdaian Rasichanh

Tresha Remsburg

Renaissance Charitable
Foundation, Inc.

Brian & Frances Richardson

Stephen & Anita Ridolfi

Susan Rudy

Ricardo Sales Santos

Kelly Sanzo

Darcy Sensenbrenner

David S. Shames

Donna Short

John Skadow

Michael D. Skokan

Steve Slocomb

Phillip Smith

Karen Somers

Sports Charities

Bradley Stafford

Minako Sumi

Lida Taghinia

Nancy Tainer

Cynthia Taylor

Lindsay Thompson

Anne M. Traynor

Roxana Tudor

Cynthia Tworek

Robert Waite

Carolyn Walker-Fitzgerald

Hong Wang

J. Donald Warren

Janet Wilbourne

Tracey Wilkinson

Daniel Williams

Erica Williams

Ed Wines

Jessica Wingate

Carly Winokur


Mitchell Zeller



HONORING THE PAST



EMBRACING THE PRESENT



Fifth World Conference on Lung Cancer



YOU ARE THE FUTURE!

Interlaken, Switzerland  August 28 - September 1, 1988

www.IASLC.org



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER